Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 29,129 matching trials from the live ClinicalTrials.gov search.
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Alemtuzumab, Tacrolimus, Mycophenolate mofetil, Sirolimus
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Conditions
Healthy
Interventions
JNJ-56021927 capsule, JNJ-56021927 tablet
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Pain, Postpartum Depression
Interventions
Ketamine (Ketalar)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Salt Lake City, Utah
Terminated Phase 1Phase 2 Interventional Results available

Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment

NCT00614666
Conditions
Coccidioidomycosis
Interventions
nikkomycin Z, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Completed Not applicable Interventional Accepts healthy volunteers

Project HOME: Home-Based Treatment Options and Mechanisms for Eating Disorders

NCT05184556
Conditions
Anorexia Nervosa, Eating Disorders
Interventions
Family-based treatment (FBT), Integrative family therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Pawtucket, Rhode Island
Conditions
Diabetes Mellitus, Type 2
Interventions
Rimonabant, Placebo (for Rimonabant), Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Light-Chain Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more
Conditions
Abdominal Pain
Interventions
Ketamine, Morphine
Drug
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Corpus Christi, Texas
Conditions
Neoplasms, Malignant Carcinoma
Interventions
Neratinib, Temsirolimus
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

NCT00536575
Conditions
Multiple Myeloma
Interventions
Bortezomib, Sorafenib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
AAV directed hLDLR gene therapy
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Putative Cognitive Enhancer VU319

NCT04051801
Conditions
Cognitive Impairment
Interventions
Dose Escalation of VU319, Dose Escalation of Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Renal Cell Carcinoma
Interventions
Decitabine, Interferon Alfa-2b
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Healthy Volunteers
Interventions
[14C]-olinciguat
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 3 Interventional Results available

Treatment for Endogenous Cushing's Syndrome

NCT01838551
Conditions
Endogenous Cushing's Syndrome
Interventions
Levoketoconazole
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Conditions
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Interventions
Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Drug
Lead sponsor
James A. Tumlin, MD
Other
Eligibility
75 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Lawrenceville, Georgia • Bethlehem, Pennsylvania
Conditions
Metastatic Solid Tumors of Metastatic Disease
Interventions
Radiation Therapy, Systemic Therapy
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
Interventions
PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more
Conditions
Radiation-Induced Xerostomia and Hyposalivation
Interventions
RXRG001, Placebo
Biological
Lead sponsor
RiboX Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Recruiting Early Phase 1 Interventional

Methamphetamine and Troriluzole

NCT06989853
Conditions
Methamphetamine Use Disorder
Interventions
Placebo, Methamphetamine
Drug
Lead sponsor
William Stoops
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Healthy
Interventions
Nemtabrutinib, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
Secondary Hyperoxaluria, Nephrolithiasis, Kidney Stones, Hyperoxaluria, Dietary Hyperoxaluria
Interventions
ALLN-177 low dose, ALLN-177 mid dose, ALLN-177 high dose, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Los Angeles, California • Daytona Beach, Florida • Jacksonville, Florida + 13 more
Conditions
Drug-drug Interaction
Interventions
tucatinib, itraconazole, rifampin, gemfibrozil, repaglinide, tolbutamide, midazolam, digoxin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder
Interventions
Full Dose MDMA, MDMA-Assisted psychotherapy, Active Placebo Dose MDMA
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
West Haven, Connecticut • Providence, Rhode Island